Share on StockTwits

ADMA Biologics (NASDAQ:ADMA) CEO Adam S. Grossman purchased 1,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average price of $9.50 per share, with a total value of $9,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Separately, analysts at Maxim Group reiterated a “buy” rating on shares of ADMA Biologics in a research note on Friday, July 11th. They now have a $15.00 price target on the stock.

ADMA Biologics (NASDAQ:ADMA) opened at 9.35 on Wednesday. ADMA Biologics has a one year low of $6.52 and a one year high of $10.75. The stock has a 50-day moving average of $9.90 and a 200-day moving average of $8.87. The company’s market cap is $86.9 million.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.